PTCHF PureTech Health plc IFRS Annual reports only
Pharmaceutical Preparations · OTC · SEC CIK 1782999 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.83M | $3.33M | $15.62M | $17.39M | $11.77M |
| R&D expense | $69.45M | $96.23M | $152.43M | $110.47M | $81.86M |
| SG&A expense | $71.47M | $53.30M | $60.99M | $57.20M | $49.44M |
| Operating income | -$136.09M | -$146.20M | -$197.81M | -$150.28M | -$119.53M |
| Interest expense | $1.73M | $3.42M | $3.94M | $4.77M | $2.95M |
| Pretax income | $23.77M | -$36.10M | -$92.78M | -$58.95M | $18.97M |
| Income tax | -$4.01M | $30.52M | -$55.72M | $3.76M | $14.40M |
| Net income | $53.51M | -$65.70M | -$50.35M | -$60.56M | $5.99M |
| EBITDA | -$132.52M | -$141.27M | -$188.91M | -$143.00M | -$112.89M |
| EPS (basic) | 0.21 | -0.24 | -0.18 | -0.21 | 0.02 |
| EPS (diluted) | 0.21 | -0.24 | -0.18 | -0.21 | 0.02 |
| Weighted avg. shares (diluted) | 256.03M | 276.30M | 284.76M | 286.59M | — |
| Balance sheet | |||||
| Cash & equivalents | $280.64M | $191.08M | $149.87M | $465.71M | $403.88M |
| Receivables | $1.52M | $2.38M | $11.87M | $3.17M | $2.56M |
| Current assets | $386.26M | $347.20M | $386.19M | $501.81M | $414.35M |
| PP&E, netmay include right-of-use assets (IFRS) | $7.07M | $9.54M | $22.96M | $26.77M | $22.78M |
| Intangibles | — | $906,000 | $831,000 | $987,000 | $899,000 |
| Total assets | $602.63M | $693.97M | $702.65M | $946.01M | $989.99M |
| Current liabilities | $41.39M | $51.37M | $96.89M | $226.13M | $180.92M |
| Short-term debt | — | $0 | $5.16M | $857,000 | $0 |
| Long-term debt | — | $0 | $10.24M | $14.26M | $14.82M |
| Total debt | — | $0 | $15.40M | $15.12M | $14.82M |
| Total liabilities | $194.70M | $235.74M | $155.06M | $361.86M | $336.45M |
| Shareholders' equity | $414.71M | $464.07M | $542.22M | $593.51M | $669.75M |
| Net debt | — | -$191.08M | -$134.47M | -$450.59M | -$389.06M |
| Shares outstanding | — | 271.85M | 278.57M | 287.80M | 285.89M |
| Cash flow statement | |||||
| Operating cash flow | -$134.37M | -$105.92M | -$178.79M | -$158.27M | -$131.83M |
| Capital expenditure | $11,000 | $70,000 | $2.18M | $5.57M | $5.17M |
| Free cash flow | -$134.38M | -$105.99M | -$180.97M | -$163.84M | -$137.00M |
| Investing cash flow | $240.89M | $68.99M | -$107.22M | $197.38M | $364.48M |
| Financing cash flow | -$16.96M | $78.14M | -$29.83M | $22.73M | $38.87M |
| Depreciation & amortization | $3.57M | $4.93M | $8.89M | $7.29M | $6.64M |
| Stock-based compensation | $22.85M | $4.42M | $14.70M | $13.95M | $10.72M |
| Share buybacks | — | — | — | — | $0 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.